Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Sprayable Gel May Help Fight off Cancer Recurrence After Surgery

A group of researchers with UCLA developed a spray gel that contains immune-stimulating drugs.

Read More »

Benefits of statins far outweigh risks

The benefits of statins in reducing the odds of heart attacks and strokes far outweigh any risks of side effects, according to a scientific statement released by the American Heart Association.

Read More »

Axovant Abandons Another Dementia Drug

Axovant Sciences’ Phase II trial of nelotanserin for the treatment of REM sleep behavior disorder in patients with Lewy body dementia failed to meet the experimental drug’s primary efficacy endpoint.

Read More »

AstraZeneca’s Imfinzi fails to meet main goals in head and neck cancer study

AstraZeneca’s immunotherapy treatment Imfinzi did not meet the main goals in a late-stage study for advanced head & neck cancer.

Read More »

Supernus’ ADHD treatment meets main goal in studies

Supernus Pharmaceuticals’ experimental drug for attention deficit hyperactivity disorder met the main goal of reducing symptoms in affected children from 6 to 11 years of age in two late-stage studies.

Read More »

AbbVie’s Rova-T Sees Another Failure

AbbVie halted a Phase III trial evaluating rovalpituzumab tesirine as a second-line therapy for advanced small-cell lung cancer after an Independent Data Monitoring Committee called for the stoppage due to shorter overall survival in the Rova-T arm.

Read More »

A Single Gene to Rule Them All: A Single Gene Might Control Obesity

Researchers at Flinders University in Australia – working with mice – removed a single gene known as RCAN1 and then fed them a variety of diets, including a high-fat diet. The mice did not gain weight, even after dramatically overeating high-fat foods over several weeks.

Read More »

Researchers May Have Found the Holy Grail of Early Cancer Detection

Researchers from the University of Queensland’s Australian Institute for Bioengineering and Nanotechnology identified a nano-scaled DNA signature that seems to be common to all cancers.

Read More »

Bayer halts vilaprisan drug trials due to toxicology data

Bayer halted trials testing the experimental uterine fibroids treatment vilaprisan, which the company previously expected to generate peak annual sales of more than 1 billion euros ($1.1 billion), citing the risk of side effects.

Read More »

In What Could Be an Alzheimer’s Breakthrough, UCLA Scientists Link Specific Gene Mutations to Dementia

Researchers with the University of California, Los Angeles (UCLA) Health Sciences have identified two major groups of genes that, when mutated, results in overproduction of the tau protein, at least in mice.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom